Raras
Buscar doenças, sintomas, genes...
Albinismo oculocutâneo
ORPHA:55CID-10 · E70.32CID-11 · EC23.20DOENÇA RARA

Albinismo oculocutâneo (AOC) descreve um grupo de doenças genéticas herdadas que afetam a produção de melanina. Ele é caracterizado por uma diminuição generalizada na pigmentação (cor) do cabelo, da pele e dos olhos, além de diferentes alterações nos olhos, como nistagmo (movimento involuntário dos olhos), visão reduzida e fotofobia (sensibilidade à luz). As variantes incluem AOC1A (a forma mais grave), AOC1B, AOC1-pigmento mínimo (AOC1-MP), AOC1-sensível à temperatura (AOC1-TS), AOC2, AOC3, AOC4, AOC5, AOC6 e AOC7.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Albinismo oculocutâneo (AOC) descreve um grupo de doenças genéticas herdadas que afetam a produção de melanina. Ele é caracterizado por uma diminuição generalizada na pigmentação (cor) do cabelo, da pele e dos olhos, além de diferentes alterações nos olhos, como nistagmo (movimento involuntário dos olhos), visão reduzida e fotofobia (sensibilidade à luz). As variantes incluem AOC1A (a forma mais grave), AOC1B, AOC1-pigmento mínimo (AOC1-MP), AOC1-sensível à temperatura (AOC1-TS), AOC2, AOC3, AOC4, AOC5, AOC6 e AOC7.

Pesquisas ativas
2 ensaios
20 total registrados no ClinicalTrials.gov
Publicações científicas
1.368 artigos
Último publicado: 2026 Mar 29
Medicamentos
3 registrados
CARBIDOPA ANHYDROUS, LEVODOPA, CARBIDOPA

Tem tratamento?

3 medicamentos registrados
Ver detalhes, fases e interações →
CARBIDOPA ANHYDROUSLEVODOPACARBIDOPA

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
5.9
Worldwide
Início
Neonatal
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: E70.32
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧬
Pele e cabelo
20 sintomas
👁️
Olhos
20 sintomas
😀
Face
1 sintomas

+ 19 sintomas em outras categorias

Características mais comuns

Nevo
Cabelo branco
Albinismo parcial
Hipopigmentação generalizada do cabelo
Cílios brancos
Hipopigmentação generalizada
60sintomas
Sem dados (60)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 60 características clínicas mais associadas, ordenadas por frequência.

NevoNevus
Cabelo brancoWhite hair
Albinismo parcialPartial albinism
Hipopigmentação generalizada do cabeloGeneralized hypopigmentation of hair
Cílios brancosWhite eyelashes

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1.368PubMed
Últimos 10 anos200publicações
Pico202578 papers
Linha do tempo
2026Hoje · 2026🧪 1976Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

8 genes identificados com associação a esta condição. Padrão de herança: Autosomal recessive.

LRMDALeucine-rich melanocyte differentiation-associated proteinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for melanocyte differentiation

LOCALIZAÇÃO

MECANISMO DE DOENÇA

Albinism, oculocutaneous, 7

A disorder of pigmentation characterized by reduced biosynthesis of melanin in the skin, hair and eyes. Patients show reduced or lacking pigmentation associated with classic albinism ocular abnormalities, including decreased visual acuity, macular hypoplasia, optic dysplasia, atypical choroidal vessels, and nystagmus.

OUTRAS DOENÇAS (1)
oculocutaneous albinism type 7
HGNC:23405UniProt:Q9H2I8
DCTL-dopachrome tautomeraseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a role in melanin biosynthesis (PubMed:33100333). Catalyzes the conversion of L-dopachrome into 5,6-dihydroxyindole-2-carboxylic acid (DHICA)

LOCALIZAÇÃO

Melanosome membraneMelanosome

VIAS BIOLÓGICAS (2)
Melanin biosynthesisRegulation of MITF-M-dependent genes involved in pigmentation
MECANISMO DE DOENÇA

Albinism, oculocutaneous, 8

A form of oculocutaneous albinism, a disorder of pigmentation characterized by reduced biosynthesis of melanin in the skin, hair and eyes. OCA8 is an autosomal recessive form characterized by mild hair and skin hypopigmentation, associated with ocular features including nystagmus, reduced visual acuity, iris transillumination, and hypopigmentation of the retina.

EXPRESSÃO TECIDUAL(Tecido-específico)
Skin Sun Exposed Lower leg
24.2 TPM
Skin Not Sun Exposed Suprapubic
23.2 TPM
Pituitária
3.0 TPM
Testículo
1.8 TPM
Brain Nucleus accumbens basal ganglia
1.6 TPM
OUTRAS DOENÇAS (1)
oculocutaneous albinism type 8
HGNC:2709UniProt:P40126
TYRTyrosinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

This is a copper-containing oxidase that functions in the formation of pigments such as melanins and other polyphenolic compounds. Catalyzes the initial and rate limiting step in the cascade of reactions leading to melanin production from tyrosine (By similarity). In addition to hydroxylating tyrosine to DOPA (3,4-dihydroxyphenylalanine), also catalyzes the oxidation of DOPA to DOPA-quinone, and possibly the oxidation of DHI (5,6-dihydroxyindole) to indole-5,6 quinone (PubMed:28661582)

LOCALIZAÇÃO

Melanosome membraneMelanosome

VIAS BIOLÓGICAS (2)
Melanin biosynthesisRegulation of MITF-M-dependent genes involved in pigmentation
MECANISMO DE DOENÇA

Albinism, oculocutaneous, 1A

An autosomal recessive disorder in which the biosynthesis of melanin pigment is absent in skin, hair, and eyes. It is characterized by complete lack of tyrosinase activity due to production of an inactive enzyme. Patients present with a life-long absence of melanin pigment after birth, and manifest increased sensitivity to ultraviolet radiation with predisposition to skin cancer. Visual anomalies include decreased acuity, nystagmus, strabismus and photophobia.

EXPRESSÃO TECIDUAL(Tecido-específico)
Skin Sun Exposed Lower leg
7.7 TPM
Skin Not Sun Exposed Suprapubic
6.6 TPM
Aorta
0.1 TPM
Testículo
0.1 TPM
Glândula salivar
0.1 TPM
OUTRAS DOENÇAS (5)
oculocutaneous albinism type 1Boculocutaneous albinism type 1Aminimal pigment oculocutaneous albinism type 1Waardenburg syndrome type 2
HGNC:12442UniProt:P14679
SLC45A2Membrane-associated transporter proteinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Proton-associated glucose and sucrose transporter (By similarity). May be able to transport also fructose (By similarity). Expressed at a late melanosome maturation stage where functions as proton/glucose exporter which increase lumenal pH by decreasing glycolysis (PubMed:32966160, PubMed:35469906). Regulates melanogenesis by maintaining melanosome neutralization that is initially initiated by transient OCA2 and required for a proper function of the tyrosinase TYR (PubMed:32966160, PubMed:354699

LOCALIZAÇÃO

Melanosome membrane

VIAS BIOLÓGICAS (1)
Melanin biosynthesis
MECANISMO DE DOENÇA

Albinism, oculocutaneous, 4

A disorder of pigmentation characterized by reduced biosynthesis of melanin in the skin, hair and eyes. Patients show reduced or lacking pigmentation associated with classic albinism ocular abnormalities, including decreased visual acuity, macular hypoplasia, optic dysplasia, atypical choroidal vessels, and nystagmus.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Baixa expressão)
Testículo
1.6 TPM
Skin Sun Exposed Lower leg
0.5 TPM
Rim - Medula
0.4 TPM
Skin Not Sun Exposed Suprapubic
0.4 TPM
Fígado
0.3 TPM
OUTRAS DOENÇAS (2)
obsolete skin/hair/eye pigmentation, variation in, 5oculocutaneous albinism type 4
HGNC:16472UniProt:Q9UMX9
OCA2P proteinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Contributes to a melanosome-specific anion (chloride) current that modulates melanosomal pH for optimal tyrosinase activity required for melanogenesis and the melanosome maturation (PubMed:11310796, PubMed:15262401, PubMed:22234890, PubMed:25513726). One of the components of the mammalian pigmentary system (PubMed:15262401, PubMed:18252222, PubMed:7601462). May serve as a key control point at which ethnic skin color variation is determined. Major determinant of brown and/or blue eye color (PubMe

LOCALIZAÇÃO

Melanosome membrane

VIAS BIOLÓGICAS (1)
Melanin biosynthesis
MECANISMO DE DOENÇA

Albinism, oculocutaneous, 2

An autosomal recessive disorder in which the biosynthesis of melanin pigment is reduced in skin, hair, and eyes. Although affected infants may appear at birth to have complete absence of melanin pigment, most patients acquire small amounts of pigment with age. Visual anomalies include decreased acuity and nystagmus. The phenotype is highly variable. The hair of affected individuals may turn darker with age, and pigmented nevi or freckles may be seen. African and African American individuals may have yellow hair and blue-gray or hazel irides. One phenotypic variant, 'brown OCA,' has been described in African and African American populations and is characterized by light brown hair and skin color and gray to tan irides.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Artéria tibial
10.5 TPM
Tireoide
9.2 TPM
Aorta
8.2 TPM
Skin Sun Exposed Lower leg
7.1 TPM
Testículo
5.3 TPM
OUTRAS DOENÇAS (6)
obsolete skin/hair/eye pigmentation, variation in, 1oculocutaneous albinism type 2Angelman syndrome due to maternal 15q11q13 deletionPrader-Willi syndrome due to maternal uniparental disomy of chromosome 15
HGNC:8101UniProt:Q04671
SLC24A5Sodium/potassium/calcium exchanger 5Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Calcium, potassium:sodium antiporter that transports 1 Ca(2+) and 1 K(+) to the melanosome in exchange for 4 cytoplasmic Na(+) (PubMed:18166528). Involved in pigmentation, possibly by participating in ion transport in melanosomes (PubMed:16357253, PubMed:18166528). Predominant sodium-calcium exchanger in melanocytes (PubMed:16357253, PubMed:18166528)

LOCALIZAÇÃO

Golgi apparatus, trans-Golgi network membraneMelanosome

VIAS BIOLÓGICAS (1)
Sodium/Calcium exchangers
MECANISMO DE DOENÇA

Albinism, oculocutaneous, 6

A disorder characterized by a reduction or complete loss of melanin in the skin, hair and eyes. Patients show reduced or lacking pigmentation often accompanied by eye symptoms such as photophobia, strabismus, moderate to severe visual impairment, and nystagmus.

EXPRESSÃO TECIDUAL(Não detectado)
Skin Not Sun Exposed Suprapubic
0.3 TPM
Skin Sun Exposed Lower leg
0.3 TPM
Testículo
0.2 TPM
Pituitária
0.1 TPM
Cérebro - Hemisfério cerebelar
0.1 TPM
OUTRAS DOENÇAS (1)
oculocutaneous albinism type 6
HGNC:20611UniProt:Q71RS6
TYRP15,6-dihydroxyindole-2-carboxylic acid oxidaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Plays a role in melanin biosynthesis (PubMed:16704458, PubMed:22556244, PubMed:23504663). Catalyzes the oxidation of 5,6-dihydroxyindole-2-carboxylic acid (DHICA) into indole-5,6-quinone-2-carboxylic acid in the presence of bound Cu(2+) ions, but not in the presence of Zn(2+) (PubMed:28661582). May regulate or influence the type of melanin synthesized (PubMed:16704458, PubMed:22556244). Also to a lower extent, capable of hydroxylating tyrosine and producing melanin (By similarity)

LOCALIZAÇÃO

Melanosome membrane

VIAS BIOLÓGICAS (2)
Melanin biosynthesisRegulation of MITF-M-dependent genes involved in pigmentation
MECANISMO DE DOENÇA

Albinism, oculocutaneous, 3

An autosomal recessive disorder in which the biosynthesis of melanin pigment is reduced in skin, hair, and eyes. Tyrosinase activity is normal and patients have only moderate reduction of pigment. The eyes present red reflex on transillumination of the iris, dilution of color of iris, nystagmus and strabismus. Darker-skinned individuals have bright copper-red coloration of the skin and hair.

EXPRESSÃO TECIDUAL(Tecido-específico)
Skin Sun Exposed Lower leg
40.8 TPM
Skin Not Sun Exposed Suprapubic
30.8 TPM
Coração - Ventrículo esquerdo
9.8 TPM
Coração - Átrio
6.8 TPM
Rim - Medula
4.8 TPM
OUTRAS DOENÇAS (2)
obsolete skin/hair/eye pigmentation, variation in, 11oculocutaneous albinism type 3
HGNC:12450UniProt:P17643
MC1RMelanocyte-stimulating hormone receptorCandidate gene tested inDesconhecido
FUNÇÃO

G protein-coupled receptor that binds melanocyte-stimulating hormones (alpha, beta, and gamma-MSH) and adrenocorticotropic hormone/ACTH, which are peptide products of the POMC precursor protein (PubMed:11442765, PubMed:11707265, PubMed:1325670, PubMed:1516719, PubMed:8463333). Upon activation, MC1R couples with the G(s) protein, stimulating adenylate cyclase and activating the cAMP-dependent signaling pathway. This activation promotes melanogenesis, resulting in the production of eumelanin (blac

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
G alpha (s) signalling eventsPeptide ligand-binding receptorsTranscriptional and post-translational regulation of MITF-M expression and activity
MECANISMO DE DOENÇA

Melanoma, cutaneous malignant 5

A malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but may also involve other sites.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
53.9 TPM
Pituitária
34.8 TPM
Cerebelo
32.6 TPM
Cérebro - Hemisfério cerebelar
29.1 TPM
Tireoide
26.9 TPM
OUTRAS DOENÇAS (4)
obsolete skin/hair/eye pigmentation, variation in, 2familial melanomaoculocutaneous albinism type 2melanoma, cutaneous malignant, susceptibility to, 5
HGNC:6929UniProt:Q01726

Medicamentos e terapias

CARBIDOPA ANHYDROUSPhase 2

Mecanismo: DOPA decarboxylase inhibitor

LEVODOPAPhase 2

Mecanismo: Dopamine D3 receptor agonist

CARBIDOPAPhase 2

Mecanismo: DOPA decarboxylase inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

530 variantes patogênicas registradas no ClinVar.

🧬 LRMDA: NM_001305581.2(LRMDA):c.609G>A (p.Leu203=) ()
🧬 LRMDA: NM_001305581.2(LRMDA):c.398+80A>G ()
🧬 LRMDA: NM_001305581.2(LRMDA):c.259-2del ()
🧬 LRMDA: NM_001305581.2(LRMDA):c.181G>A (p.Asp61Asn) ()
🧬 LRMDA: NM_001305581.2(LRMDA):c.661dup (p.Ile221fs) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 924 variantes classificadas pelo ClinVar.

739
185
Patogênica (80.0%)
VUS (20.0%)
VARIANTES MAIS SIGNIFICATIVAS
OCA2: NM_000275.3(OCA2):c.2338G>A (p.Gly780Ser) [Likely pathogenic]
TYR: NM_000372.5(TYR):c.605A>T (p.His202Leu) [Likely pathogenic]
SLC45A2: NM_016180.5(SLC45A2):c.1238G>A (p.Gly413Glu) [Likely pathogenic]
OCA2: NM_000275.3(OCA2):c.2063T>C (p.Leu688Pro) [Pathogenic]
TYR: NM_000372.5(TYR):c.265del (p.Cys89fs) [Pathogenic]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 27
1Fase 11
·Pré-clínico5
Medicamentos catalogadosEnsaios clínicos· 3 medicamentos · 10 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Albinismo oculocutâneo

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

20 ensaios clínicos encontrados, 2 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
599 papers (10 anos)
#1

Oculocutaneous albinism variants in 28 consanguineous families and functional classification of a pathogenic deep intron variant in TYR.

European journal of human genetics : EJHG2026 Mar 11

Oculocutaneous albinism (OCA) are genetically and clinically heterogeneous recessive disorders with at least 23 associated genes. Isolated OCA is characterized by hypopigmentation in the skin, hair, and eyes combined with ocular abnormalities. Hermansky Pudlak syndrome (HPS) and Chediak-Higaski syndrome are syndromic forms of OCA, distinguished by immunological and hematological symptoms in addition to hypopigmentation and ocular anomalies. Targeted clinical care is crucial for the patients and molecular genetic diagnosis is important for classification of patients. Current diagnostic yield is approximately 70%, and a high proportion of patients are heterozygous for pathogenic variants in OCA genes, suggesting the presence of disease-causing non-coding variants. We describe here next generation sequencing (NGS) analysis, including copy number variant (CNV) analysis, of 28 consanguineous families, comprising a total of 136 individuals presenting with OCA. We provide a molecular genetic diagnosis in all 28 families. Noteworthy, five families (18%) had pathogenic variants in a gene associated with HPS, showing the importance of an in-depth molecular genetic investigation, which should be offered to persons with albinism. Furthermore, we report the first deep intron variant in TYR causing OCA and show by minigene analysis that the variant causes inclusion of a pseudoexon.

#2

Insights from Computational Dynamic Active Site Mapping into Substrate Recognition and Mutation-Induced Dysfunction in Human Tyrosinase.

International journal of molecular sciences2026 Feb 18

The ability of enzymes to recognize and process structurally diverse substrates is fundamental to metabolic flexibility and biological regulation. In melanin biosynthesis, human tyrosinase (Tyr) catalyzes the oxidation of several chemically distinct intermediates, including L-tyrosine, L-DOPA, DHICA, and DHI. Although its catalytic chemistry is well established, the structural basis of substrate selectivity and how it is altered by disease-associated mutations remains unclear. Using molecular docking and molecular dynamics simulations, we mapped the Tyr active site and identified 23 evolutionarily conserved residues that mediate multi-substrate recognition and binding. Across all substrates, binding induces coordinated conformational responses, particularly within an anchoring region (334-347) that provides electrostatic and hydrophobic steering, and a flexible gating loop (374-386) that modulates access and stabilizes bound intermediates. The OCA1B-associated P406L mutation, although distant from the catalytic core, disrupts long-range dynamic coupling and impairs loop flexibility, while 25 ClinVar-listed genetic variants at substrate-interacting residues weaken active-site organization, underscoring the sensitivity of Tyr's dynamic network to perturbation. Integrating these findings, we propose an ordered multi-substrate binding mechanism in which substrates are first guided by the anchoring region, then aligned by the universal triad, and finally refined through loop-mediated, substrate-specific contacts. Our work suggests a dynamic framework that could be useful for understanding human tyrosinase catalysis, genetic mutation impact, and future engineering strategies.

#3

A Dosage-Dependent Dominant-Negative Mechanism of SLC45A2(W74R) in Autosomal Dominant Oculocutaneous Albinism Revealed by Zebrafish Modeling.

Translational vision science &amp; technology2026 Feb 02

To investigate the clinical characteristics of autosomal dominant oculocutaneous albinism (OCA) and functionally validate the heterozygous SLC45A2(W74R) variant using a zebrafish model. Three members of a Korean family with OCA underwent comprehensive clinical examinations. Targeted panel and genome sequencing were performed on the proband, and Sanger sequencing was performed on all affected family members. To assess the pathogenicity of the genetic variant, a slc45a2 knockout (KO) zebrafish model was generated using CRISPR technology. All three affected patients exhibited hair and iris hypopigmentation, with variable foveal hypoplasia and nystagmus. A heterozygous c.220T>C:p.(W74R) variant in SLC45A2 was identified and was absent in gnomAD v4.1. Multiple in silico predictions supported its pathogenicity (AlphaMissense: 0.993, CADD: 29.6, REVEL: 0.951). Genome sequencing revealed no additional pathogenic or common hypomorphic variants in other known OCA-related genes. The slc45a2 KO zebrafish exhibited a typical albino phenotype, which was rescued by melanocyte-specific expression of normal SLC45A2 but not by the SLC45A2(W74R) variant. Furthermore, the SLC45A2(W74R) variant suppressed pigmentation in heterozygous KO, but not in wild-type zebrafish, indicating a dominant-negative effect in a dosage-dependent manner. This study demonstrated that a heterozygous c.220T>C:p.(W74R) variant in SLC45A2 causes variable expressivity of OCA in a dominant inherited manner, and this variant interferes with melanogenesis in zebrafish. This study expands the mode of inheritance in OCA and provides crucial functional validation that is important for genetic counseling.

#4

Correction of Abnormal Head Position in Pediatric Nystagmus Using Yoked Low-Value Prism Glasses: A Retrospective Study.

Investigative ophthalmology &amp; visual science2026 Feb 02

Nystagmus involves abnormal head positions (AHPs) toward the null point for improving visual acuity. While surgical interventions are the standard therapy, the use of yoked prisms is a possibility not often used. Our team used low-value prisms in children to mitigate AHP. Yoked prisms were tailored to the direction of head turn. Thirty-one children were reviewed. Outcomes were binocular best-corrected visual acuity (BBCVA) and AHP measures with and without prisms. Of the 31 patients aged 10.3 ± 3.6 years (16 male), 19 were diagnosed with idiopathic infantile nystagmus syndrome, 6 with oculocutaneous albinism, and 6 with other secondary nystagmus. Prism's average prescription was 3.9 ± 1.25 diopters. BBCVA for distance averaged 0.44 ± 0.22 logMAR, improving to 0.41 ± 0.23 logMAR (P = 0.001, small size effect). AHP reduced from 16.9° ± 9.9° to 4.6° ± 5.8° for distance vision (P < 0.0001) and 12.7° ± 12.9° to 3.8° ± 6.2° for near vision (P < 0.0001), both with large size effects. The angle of the prisms most frequently prescribed was 180° (26 cases), as well as 2 cases at 135°, 1 case at 30°, and 2 cases at 90°. Our study found an improvement in AHP using low-value prisms in a pediatric population with nystagmus. Allowing the use of primary gaze position, prisms may be a therapeutic option to reduce the physical and social difficulties from AHP in these cases. This study provides the first quantitative assessment of the minimal prism values required to significantly reduce abnormal head posture in nystagmus, offering a valuable adjunctive treatment option for these patients.

#5

Sentinel Nystagmus: The Key to Identifying Type II Oculocutaneous Albinism (OCA2) in the Pediatric Setting.

Case reports in pediatrics2026

To present a case of type II oculocutaneous albinism (OCA2) diagnosed in infancy following the finding of nystagmus, and to review the diagnostic process and the management of this disorder. A 4-month-old female presented with subtle, roving eyes that were initially attributed to normal development. A subsequent evaluation by a pediatric ophthalmologist, prompted by a high index of suspicion, confirmed the findings of nystagmus, mild foveal hypoplasia, and astigmatism. Genetic testing confirmed the presence of pathological variants of the OCA2 gene, leading to a diagnosis of oculocutaneous albinism. This case highlights the importance of a meticulous ophthalmologic examination and a high index of suspicion in pediatric care. The early finding of nystagmus can be the key to a timely diagnosis of OCA2. This allows for early intervention to optimize visual development and allows for multidisciplinary management and genetic counseling for the family. This case underscores the need for ongoing education in enhancing the early detection of OCA.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC618 artigos no totalmostrando 195

2026

Quantifying functional vision in a mouse model of oculocutaneous albinism type 1.

Scientific reports
2026

The impact of stigma on people with albinism in Africa: a narrative review.

Journal of community genetics
2026

Oculocutaneous albinism variants in 28 consanguineous families and functional classification of a pathogenic deep intron variant in TYR.

European journal of human genetics : EJHG
2026

Common dominant-negative spectrum of SLC45A2 mutations in OCA4 defined by endoplasmic reticulum retention.

Biochemical and biophysical research communications
2026

Insights from Computational Dynamic Active Site Mapping into Substrate Recognition and Mutation-Induced Dysfunction in Human Tyrosinase.

International journal of molecular sciences
2026

A Dosage-Dependent Dominant-Negative Mechanism of SLC45A2(W74R) in Autosomal Dominant Oculocutaneous Albinism Revealed by Zebrafish Modeling.

Translational vision science &amp; technology
2026

Cataract surgery with implantation of small aperture acrylic hydrophobic IOL to reduce photophobia in a patient affected by oculocutaneous albinism.

American journal of ophthalmology case reports
2025

Successful treatment of invasive squamous cell carcinoma and diffuse actinic keratoses by sequential ALA-PDT combined with surgery in a patient with oculocutaneous albinism.

European journal of dermatology : EJD
2026

Aggressive Amelanotic Melanoma in a Patient with Oculocutaneous Albinism Type 1A: A Case with Limited Response to Targeted and Immunotherapy.

Clinical and experimental dermatology
2026

Sentinel Nystagmus: The Key to Identifying Type II Oculocutaneous Albinism (OCA2) in the Pediatric Setting.

Case reports in pediatrics
2026

First Report of Oculocutaneous Albinism Type I Among Baka Pygmies From Cameroon.

Pigment cell &amp; melanoma research
2026

Griscelli syndrome type 2: A rare case report of pediatric immunodeficiency and neurological implications.

Medicine
2025

Concentric macular rings and OCT corrugations in foveal hypoplasia: proof of concept for an optical interference mechanism.

International journal of retina and vitreous
2026

Resolving Complex Retinal Alleles via Long-Read Sequencing.

JAMA ophthalmology
2025

Generation and ophthalmological characterization of oculocutaneous albinism type 1 pig models by selection-free genome editing.

Scientific reports
2025

OCA2 deficiency enhances TPC2 channel activity to reduce melanosomal pH and pigment production.

The Journal of investigative dermatology
2025

The prevalence of epidermal skin malignancies in people living with oculocutaneous albinism attending the Universitas Academic Hospital, Bloemfontein, South Africa.

Dermatology reports
2025

Updated Analysis of Albinism in Japan: 290 Families With Novel Pathological Variants.

Pigment cell &amp; melanoma research
2025

Ampyrone (4-Aminoantipyrine) is a Direct Agonist of Human Tyrosinase and Potential Therapeutic for Oculocutaneous Albinism and Disorders of Hypopigmentation.

bioRxiv : the preprint server for biology
2025

Analysis of multi-trait evolution across independently evolved cavefish populations reveals shared and independent evolution of suites of cave-associated traits.

bioRxiv : the preprint server for biology
2025

A novel homozygous HPS4 mutation in Hermansky-Pudlak syndrome: case report and literature review.

Therapeutic advances in respiratory disease
2025

Fatal Chronic Varicella-Zoster Viral Infection in a Young Man With Chediak-Higashi Syndrome.

Pediatric dermatology
2025

A novel HPS3 pathogenic nonsense variant associated with Hermansky-Pudlak syndrome type 3 and a platelet dysfunction.

Molecular biology reports
2026

Genetic Pigmentary Disorders: From Molecular Mechanisms to Clinical Manifestations.

The Journal of dermatology
2025

Retinal Pigment Epithelium-Targeting Gene Therapy Corrects Ocular Symptoms in Mouse and Rat Models of Oculocutaneous Albinism Type I.

MedComm
2025

Hermansky-Pudlak Syndrome.

Clinics in chest medicine
2025

A recessive coat color dilution in Dexter cattle attributed to a missense mutation in SLC45A2.

Animal genetics
2025

Alterations of Photoreceptor Synaptic Ribbons in the Retina of a Human Patient With Oculocutaneous Albinism Type 1 (OCA1).

Investigative ophthalmology &amp; visual science
2026

Reduced gene expression and missense mutations in the transporter protein SLC45A2 in a hypopigmented Egyptian rousette fruit bat (Rousettus aegyptiacus).

The Journal of heredity
2025

Identification of a RAB32-LRMDA-Commander membrane trafficking complex reveals the molecular mechanism of human oculocutaneous albinism type 7.

Nature communications
2025

TYROSINASE-Deficient Human Retinal Pigment Epithelium Exhibits Melanosome Maturation Defects.

Investigative ophthalmology &amp; visual science
2025

Hermansky-Pudlak syndrome-rare type 10 with AP3D1 mutation.

Oxford medical case reports
2025

Spontaneous mutant in threespine stickleback connects endosome trafficking disorders and inflammatory bowel diseases via changes in the gut microbiome.

bioRxiv : the preprint server for biology
2025

From paleness to albinism: Contribution of OCA2 exon 10 skipping to hypopigmentation.

PLoS genetics
2025

Clinical characteristics and prognostic factors of Hermansky-Pudlak syndrome with or without pulmonary fibrosis: a systematic review.

Therapeutic advances in respiratory disease
2025

Rare phenotypes of white coat color in Simmental calves: genetic causes of syndromic forms of albinism and depigmentation.

Molecular genetics and genomics : MGG
2025

Rapid Diagnosis and Subtyping of Hermansky-Pudlak Syndrome With Flow Cytometry Analysis.

Pigment cell &amp; melanoma research
2025

Generation of a human iPSC line, INMi007-A, carrying compound heterozygous DCT variants associated with oculocutaneous albinism type 8.

Stem cell research
2025

Genetic Diagnosis of Oculocutaneous Albinism Type 1A: A Novel TYR Variant.

Clinical case reports
2026

Line-Field Confocal Optical Coherence Tomography (LC-OCT) of Amelanotic Melanoma in a Patient With Oculocutaneous Albinism.

International journal of dermatology
2025

Oculocutaneous albinism in a patient with an OCA2 variant: molecular and clinical insights.

Asian biomedicine : research, reviews and news
2025

Contribution of Cytology to the Diagnosis of Chediak-Higashi Syndrome.

Cureus
2025

Refractory Colitis in Hermansky-Pudlak Syndrome: A Surgical Case Report.

Cureus
2025

Griscelli Syndrome: A Case Report from Pakistan, A Review of the Literature, and an Approach to Hematological Disorders Associated With Albinism.

Cureus
2025

A murine model lacking Lyst recapitulates Chediak-Higashi syndrome with an earlier-onset neurodegenerative phenotype.

Communications biology
2025

Genetic mutations disrupt the coordinated mode of tyrosinase's intra-melanosomal domain.

Protein science : a publication of the Protein Society
2025

Kidney melanosis associated with a novel HSP-1 Hermansky-Pudlak oculocutaneous albinism mutation: a case report.

BMC nephrology
2025

Non-melanoma skin cancer and HPV in persons with albinism: a call for research investment.

British journal of cancer
2025

Genetics of Skin, Hair, and Eye Color in Human Pigmentation Disorders.

Annals of human genetics
2025

Genetic mutations disrupt the coordinated mode of tyrosinase intra-melanosomal domain.

bioRxiv : the preprint server for biology
2025

Strabismus and nystagmus in oculocutaneous albinism: clinical perspectives, diagnosis, and role of neurotransmitters.

Neurogenetics
2025

Differences in Visual Acuity Among Hermansky-Pudlak Syndrome Subtypes.

Cureus
2025

Comprehensive analysis of a novel LYST mutation in a Tunisian patient with Chediak-Higashi syndrome.

BMC medical genomics
2025

Typical presentation of autosomal recessive oculocutaneous albinism in two siblings.

GMS ophthalmology cases
2025

Alteration of Hair Melanin in Patients With Mowat-Wilson Syndrome: The Role of the ZEB2 Gene in Regulating Melanogenesis Through SLC45A2.

Pigment cell &amp; melanoma research
2025

Amelanotic Melanoma in Oculocutaneous Albinism: Clinical Presentation and Diagnostic Pitfalls with Dermoscopic-Histopathological Correlation.

Dermatology practical &amp; conceptual
2025

Hermansky-Pudlak Syndrome: From Molecular Pathogenesis to Targeted Therapies.

IUBMB life
2025

A novel 5bp deletion in HPS4 gene associates with Hermansky-Pudlak Syndrome.

Ophthalmic genetics
2025

[Analysis of TYR gene variant in a patient with Oculocutaneous albinism].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2025

Compound heterozygosity in type-II oculocutaneous albinism.

Indian journal of dermatology, venereology and leprology
2025

Clinico-pathologic profile of skin cancers in oculocutaneous albinism at Universitas Academic Hospital.

Health SA = SA Gesondheid
2025

Age-related neutrophil activation in Hermansky-Pudlak Syndrome Type-1.

Orphanet journal of rare diseases
2025

Molecular Characterization of Oculocutaneous Albinism in Consanguineous Pakistani Families: Unraveling Disease-Causing Pathogenic Variants in OCA2 and TYR Genes for Precision Diagnosis.

Biochemical genetics
2025

Platelet secretion defects and increased CD63 expression in Hermansky-Pudlak syndrome: a case report.

Blood coagulation &amp; fibrinolysis : an international journal in haemostasis and thrombosis
2025

Case Report: Genetic analysis of oculocutaneous albinism type 2 caused by a new mutation in the OCA2.

Frontiers in pediatrics
2025

Trichilemmal Carcinoma in a Patient With Oculocutaneous Albinism.

Cureus
2025

A 29-Year-Old Man With Type 2 Hermansky-Pudlak Syndrome and Wolff-Parkinson-White Syndrome: The Hypothesis of a Potential Link Between These Two Conditions.

Case reports in medicine
2025

Oculocutaneous albinism type 1B associated with allelic combination of a risk haplotype.

Journal of dermatological science
2025

Prediction of Skin Color Using Forensic DNA Phenotyping in Asian Populations: A Focus on Thailand.

Biomolecules
2025

Multiplexed Assays of Variant Effect and Reclassification of TYR Variants in Chinese Patients with Oculocutaneous Albinism.

The Journal of investigative dermatology
2025

Hermansky-Pudlak syndrome (HPS): a rare genetic interstitial lung disease.

BMJ case reports
2025

Chediak-Higashi Syndrome: a Comprehensive Case Report and Literature Review.

Clinical laboratory
2025

Unusual Autosomal Dominant Inheritance of Oculocutaneous Albinism Type 4 (OCA-4): Clinical and Functional Features From A Chinese Family.

Pigment cell &amp; melanoma research
2025

Case report: Inflammatory bowel disease in Hermansky-Pudlak syndrome type 3 due to novel variant in HPS3.

Frontiers in genetics
2025

Albinism research in a Southern African setting: unique findings.

Journal of community genetics
2025

Arcuate pattern of retinal ganglion cell axons in oculocutaneous albinism has implications for axon pathfinding.

BMJ case reports
2025

Hypopigmented malignant melanoma in a patient with oculocutaneous albinism type 4.

The Journal of dermatology
2025

Hermansky-Pudlak Syndrome Type 1 Presenting with Interstitial Lung Disease: A Report of a Rare Case from Saudi Arabia.

The American journal of case reports
2025

Molecular insights into genodermatoses: Genetic findings from 43 patients.

Archives of dermatological research
2025

Screening of Clinical Data of Patients with Abnormal Head Posture and Investigation of Abnormal Head Posture Change After Treatment.

Turkish journal of ophthalmology
2025

Synonymous but Significant: New Findings of Pathological Variants in Hermansky-Pudlak Syndrome.

Pigment cell &amp; melanoma research
2025

Management of an advanced case of basal cell carcinoma in a patient with albinism: Considerations for working in low- and middle-income countries.

JAAD case reports
2025

Chiasmal Decussation in Oculo-Cutaneous Albinism Type 8.

Investigative ophthalmology &amp; visual science
2025

A Recessive oca2 Mutation Underlies Albinism in Xiphophorus fish.

bioRxiv : the preprint server for biology
2025

Advancing Insights into Pediatric Macular Diseases: A Comprehensive Review.

Journal of clinical medicine
2025

Human recombinant tyrosinase destabilization caused by the double mutation R217Q/R402Q.

Protein science : a publication of the Protein Society
2024

Griscelli syndrome: Erdheim-Chester disease-like local presentation progressing to accelerated phase.

The Turkish journal of pediatrics
2024

Role of Morphology in the Diagnosis of an Unsuspected Case of Chediak-Higashi Syndrome: A Case Report.

Cureus
2024

Efficient genome editing in medaka (Oryzias latipes) using a codon-optimized SaCas9 system.

Journal of Zhejiang University. Science. B
2024

Genotypic and phenotypic analysis of an oculocutaneous albinism patient: a case report and review of the literature.

Journal of medical case reports
2024

Syndromic Association of Depigmentation With Congenital Hearing Loss: A Review of Three Children With Auditory Pigmentary Disorders.

Ear, nose, &amp; throat journal
2025

Curation of OCA2 Variants of Uncertain Significance From Chinese Oculocutaneous Albinism Patients Based on Multiplex Assays.

Pigment cell &amp; melanoma research
2024

Chedíak-Higashi Syndrome: Hair-to-toe spectrum.

Seminars in pediatric neurology
2024

Application of Forced Oscillation Technique in Assessing Pulmonary Fibrosis in Hermansky-Pudlak Syndrome.

Advances in respiratory medicine
2024

Ancestral origins of TYR and OCA2 gene mutations in oculocutaneous albinism from two admixed populations in Colombia.

PloS one
2025

A 65 kilobase deletion of the upstream TYR gene region in a family with oculocutaneous albinism type 1.

Gene
2024

Granulomatous Colitis Due to Hermansky-Pudlak Syndrome.

ACG case reports journal
2024

Early diagnosis of immunodeficient patients with partial albinism: The role of hair study and peripheral blood smear.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
2024

Common Variants in the TYR Gene with Unclear Pathogenicity as the Cause of Oculocutaneous Albinism in a Cohort of Russian Patients.

Biomedicines
2024

Modulating OCA2 Expression as a Promising Approach to Enhance Skin Brightness and Reduce Dark Spots.

Biomolecules
2024

Acute Angle Closure Glaucoma Attack in a Patient With Hermansky-Pudlak Syndrome: A Case Report.

Cureus
2024

Albinism and Blood Cell Profile: The Peculiar Case of Asinara Donkeys.

Animals : an open access journal from MDPI
2024

Tyrp1 is the mendelian determinant of the Axolotl (Ambystoma mexicanum) copper mutant.

Scientific reports
2024

Biallelic TYR and TKFC variants in Egyptian patients with OCA1 and new expanded TKFC features.

BMC genomics
2025

The degradation of TYR variants derived from Chinese OCA families is mediated by the ERAD and ERLAD pathway.

Gene
2024

Altered Functional Responses of the Retina in B6 Albino Tyrc/c Mice.

Investigative ophthalmology &amp; visual science
2024

A novel deletion in the BLOC1S6 Gene Associated with Hermansky-Pudlak syndrome type 9 (HPS-9).

BMC genomics
2024

Hermansky-Pudlak Syndrome Type 2: A Case Report on an Ultra-Rare Disorder.

Cureus
2024

Hermansky-Pudlak Syndrome: A Rare Congenital Disorder With Interstitial Lung Disease.

Cureus
2024

Mutational spectrum associated with oculocutaneous albinism and Hermansky-Pudlak syndrome in nine Pakistani families.

BMC ophthalmology
2025

A case of metastasis of giant basal cell carcinoma in oculocutaneous albinism.

The Journal of dermatology
2024

Identifying genetic defects in oculocutaneous albinism patients of West Bengal, Eastern India.

Molecular biology reports
2024

After an initial Hermansky-Pudlak syndrome clinical diagnosis, molecular testing reveals variants for oculocutaneous albinism type 1B: A case report.

Molecular genetics &amp; genomic medicine
2024

Genetic Linkage between CAPN5 and TYR Variants in the Context of Albinism and Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy Absence: A Case Report.

International journal of molecular sciences
2024

Functional analysis of two mutation sites in the OCA2 gene.

Scientific reports
2024

Genetic screening reveals hotspot variants and prevalence rates of Hermansky-Pudlak syndrome in the Chinese population.

Clinica chimica acta; international journal of clinical chemistry
2024

Nystagmus and Foveal Hypoplasia in a Carrier of Oculocutaneous Albinism.

Ophthalmic surgery, lasers &amp; imaging retina
2024

Successful treatment of retinopathy of prematurity in oculocutaneous albinism with OCA2 variants: a case report and review of literature.

BMC pediatrics
2024

Two-pore channel 2 is required for soluble adenylyl cyclase-dependent regulation of melanosomal pH and melanin synthesis.

Pigment cell &amp; melanoma research
2024

A patient with albinism and retinitis pigmentosa, a case report.

American journal of ophthalmology case reports
2024

Genotypic spectrum of albinism in Mali.

Pigment cell &amp; melanoma research
2024

Hermansky-Pudlak Syndrome with an Improvement in the Respiratory Symptoms after the Administration of Pirfenidone.

Internal medicine (Tokyo, Japan)
2024

[Correlation between refraction and axial length in Albinos].

Journal francais d'ophtalmologie
2024

Cataract surgery and artificial iris implantation in patient with oculocutaneous albinism: a case report.

Arquivos brasileiros de oftalmologia
2024

Clinical and mutational characteristics of oculocutaneous albinism type 7.

Scientific reports
2024

Runs of Homozygosity Detection and Selection Signature Analysis for Local Goat Breeds in Yunnan, China.

Genes
2024

Sodium fluorescein dye as an adjunct in vitrectomy for rhegmatogenous retinal detachment in oculocutaneous albinism.

Oman journal of ophthalmology
2024

Genetic insights into Tietz albinism-deafness syndrome: A new dominant-negative mutation in MITF.

Pigment cell &amp; melanoma research
2024

Amelanotic melanoma in oculocutaneous albinism type 4 detected using violet-light dermoscopy.

The Journal of dermatology
2024

Unsuccessful transscleral cyclophotocoagulation in oculocutaneous albinism.

American journal of ophthalmology case reports
2024

Identification of Candidate Genes for Red-Eyed (Albinism) Domestic Guppies Using Genomic and Transcriptomic Analyses.

International journal of molecular sciences
2023

[A case for the inclusion of oculocutaneous albinism as a skin-related Neglected Tropical Disease].

Medecine tropicale et sante internationale
2024

Oculocutaneous albinism type 4: Novel compound heterozygous mutations in the SLC45A2 gene in a Chinese case.

Molecular genetics &amp; genomic medicine
2024

Genetic analysis of albinism caused by compound heterozygous mutations of the OCA2 gene in a Chinese family.

Hereditas
2024

Generation and characterization of retinal pigment epithelium from patient iPSC line to model oculocutaneous albinism (OCA)1A disease.

Journal of biosciences
2024

Segmental hypopigmentation and unilateral fibrous patches: an unusual presentation of tuberous sclerosis complex with a novel TSC2 mutation.

International journal of dermatology
2024

Visual acuity improvement in children with albinism beyond the first decade of life.

PloS one
2024

Integrative functional genomic analyses identify genetic variants influencing skin pigmentation in Africans.

Nature genetics
2024

TYR mutation in a Chinese population with oculocutaneous albinism: Molecular characteristics and ophthalmic manifestations.

Experimental eye research
2023

Does Foveal Hypoplasia Affect Emmetropization in Patients with Albinism?

Children (Basel, Switzerland)
2024

Genetic landscape of forensic DNA phenotyping markers among Mediterranean populations.

Forensic science international
2024

Integrated sun protection advice for the South African population.

International journal of dermatology
2023

Clusters of oculocutaneous albinism in isolated populations in Brazil: A community genetics challenge.

Genetics and molecular biology
2023

Management of Severe Neutropenia in a Child With Chediak-Higashi Syndrome Using Granulocyte-Colony Stimulating Factor (G-CSF): A Case Report.

Cureus
2024

Unraveling Hermansky-Pudlak syndrome type 7: a case report and comprehensive literature review on the identification of DTNBP1 variants.

Ophthalmic genetics
2024

Novel Variants of HPS6 Cause Suspected Ocular Albinism: A Report of 2 Cases and the Profile of HPS6 Variants.

Ophthalmic research
2024

Reduction of lens size in PAX6-related aniridia.

Experimental eye research
2024

The molecular landscape of oculocutaneous albinism in India and its therapeutic implications.

European journal of human genetics : EJHG
2024

Comparative transcriptome analysis reveals growth and molecular pathway of body color regulation in turbot (Scophthalmus maximus) exposed to different light spectrum.

Comparative biochemistry and physiology. Part D, Genomics &amp; proteomics
2024

Daylight photodynamic therapy as a treatment for actinic field change in patients diagnosed with oculocutaneous albinism in sub-Saharan Africa.

Clinical and experimental dermatology
2023

The Impact of WhatsApp as a Health Education Tool in Albinism: Interventional Study.

JMIR dermatology
2024

Unveiling genetics of non-syndromic albinism using whole exome sequencing: A comprehensive study of TYR, TYRP1, OCA2 and MC1R genes in 17 families.

Gene
2023

Hermansky-Pudlak Syndrome Type 6 and Renal Failure: A Rare Genetic Disease.

Cureus
2023

[Diagnosis of a case with Hermansky-Pudlak syndrome type 5 through high-throughput sequencing and a literature review].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2024

Novel compound heterozygous mutations in OCA2 gene were identified in a Chinese family with oculocutaneous albinism.

Molecular genetics &amp; genomic medicine
2023

Genetic and dermoscopic findings in a case series of children with oculocutaneous albinism.

Pediatric dermatology
2024

Ultra-widefield fundus image of an oculocutaneous albinism patient with rhegmatogenous retinal detachment.

Journal francais d'ophtalmologie
2023

Oculocutaneous albinism in a Puerto Rican patient.

JAAD case reports
2023

Foveal Hypoplasia in a Child With Tyrosinase-Positive Albinism.

Cureus
2024

Spectrum of LYST mutations in Chediak-Higashi syndrome: a report of novel variants and a comprehensive review of the literature.

Journal of medical genetics
2024

Periocular hypopigmentation of the elderly (POHE): A case series.

Journal of the European Academy of Dermatology and Venereology : JEADV
2023

Stacked implantation of two prosthetic iris devices for patients with iris defects: A modified surgical technique.

American journal of ophthalmology case reports
2023

Ophthalmologic Phenotype-Genotype Correlations in Patients With Oculocutaneous Albinism Followed in a Reference Center.

Investigative ophthalmology &amp; visual science
2023

Evaluating the Cysteine-Rich and Catalytic Subdomains of Human Tyrosinase and OCA1-Related Mutants Using 1 μs Molecular Dynamics Simulation.

International journal of molecular sciences
2023

Vision-Related Quality of Life in Danish Patients with Albinism and the Impact of an Updated Optical Rehabilitation.

Journal of clinical medicine
2024

Unsuspected consequences of synonymous and missense variants in OCA2 can be detected in blood cell RNA samples of patients with albinism.

Pigment cell &amp; melanoma research
2023

Forensic DNA Phenotyping: Genes and Genetic Variants for Eye Color Prediction.

Genes
2023

Black Piedra in an Amerindian Girl with Oculocutaneous Albinism Type 2.

Dermatology practical &amp; conceptual
2023

Impaired Direction Selectivity in the Nucleus of the Optic Tract of Albino Mice.

Investigative ophthalmology &amp; visual science
2023

Genetic variants in melanogenesis proteins TYRP1 and TYR are associated with the golden rhesus macaque phenotype.

G3 (Bethesda, Md.)
2023

Mutational Analysis of TYR, OCA2, SLC45A2, and TYRP1 Genes Identifies Novel and Reported Mutations in Chinese Families with Oculocutaneous Albinism.

Alternative therapies in health and medicine
2023

Determining a Worldwide Prevalence of Oculocutaneous Albinism: A Systematic Review.

Investigative ophthalmology &amp; visual science
2023

Structural insights into pink-eyed dilution protein (Oca2).

Bioscience reports
2023

Identification and characterization of the compound heterozygous variants of TYR gene in a northern Chinese family with Oculocutaneous albinism type 1.

Pigment cell &amp; melanoma research
2025

Recent Advances in Clinical Research on Rare Intractable Hereditary Skin Diseases in Japan.

The Keio journal of medicine
2023

Tilted disc in eyes with fovea plana.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
2023

Haplotype-based analysis resolves missing heritability in oculocutaneous albinism type 1B.

American journal of human genetics
2024

FOVEA PLANA AND FUNDUS HYPOPIGMENTATION IN PRADER-WILLI SYNDROME.

Retinal cases &amp; brief reports
2023

Chediak-Higashi syndrome.

Current opinion in hematology
2023

A review of treatment of port-wine stains with pulsed dye laser in fitzpatrick skin type IV-VI.

Archives of dermatological research
2023

Annular Erythematous Plaques With Central Hypopigmentation on Sun-Exposed Skin.

Cutis
2023

Evolving red papule in a patient with oculocutaneous albinism.

Pediatric dermatology
2023

Hermansky-Pudlak syndrome with early onset inflammatory bowel disease due to loss of dysbindin expression.

European journal of medical genetics
2023

Oculocutaneous albinism: the neurological, behavioral, and neuro-ophthalmological perspective.

European journal of pediatrics
2023

Association between Variants in the OCA2-HERC2 Region and Blue Eye Colour in HERC2 rs12913832 AA and AG Individuals.

Genes
2023

Low-vision intervention for oculocutaneous albinism in a Tertiary Eye Care Hospital in India.

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
2023

cDNA sequencing increases the molecular diagnostic yield in Chediak-Higashi syndrome.

Frontiers in genetics
2023

Identification of novel variations of oculocutaneous albinism type 2 with Prader-Willi syndrome/Angelman syndrome in two Chinese families.

Frontiers in genetics
2022

Abstracts from the 2022 European Association for Vision and Eye Research Festival, 13-15 October 2022, Valencia.

Acta ophthalmologica
2023

[Clinical and molecular genetic analysis of Angelman syndrome with oculocutaneous albinism type 2: A case report and literature review].

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
2023

Report of Hermansky-Pudlak Syndrome in Two Families with Novel Variants in HPS3 and HPS4 Genes.

Genes
2023

Diagnostic Yield of Genetic Testing for Ocular and Oculocutaneous Albinism in a Diverse United States Pediatric Population.

Genes
2022

In Vitro Reconstitution of the Melanin Pathway's Catalytic Activities Using Tyrosinase Nanoparticles.

International journal of molecular sciences
2022

Oculo-Cutaneous Albinism Type 4 (OCA4): Phenotype-Genotype Correlation.

Genes
2023

A homozygous AP3D1 missense variant in patients with sensorineural hearing loss as the leading manifestation.

Human genetics
Ver todos os 618 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Albinismo oculocutâneo.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Albinismo oculocutâneo

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Oculocutaneous albinism variants in 28 consanguineous families and functional classification of a pathogenic deep intron variant in TYR.
    European journal of human genetics : EJHG· 2026· PMID 41807736mais citado
  2. Insights from Computational Dynamic Active Site Mapping into Substrate Recognition and Mutation-Induced Dysfunction in Human Tyrosinase.
    International journal of molecular sciences· 2026· PMID 41752073mais citado
  3. A Dosage-Dependent Dominant-Negative Mechanism of SLC45A2(W74R) in Autosomal Dominant Oculocutaneous Albinism Revealed by Zebrafish Modeling.
    Translational vision science &amp; technology· 2026· PMID 41705770mais citado
  4. Correction of Abnormal Head Position in Pediatric Nystagmus Using Yoked Low-Value Prism Glasses: A Retrospective Study.
    Investigative ophthalmology &amp; visual science· 2026· PMID 41626872mais citado
  5. Sentinel Nystagmus: The Key to Identifying Type II Oculocutaneous Albinism (OCA2) in the Pediatric Setting.
    Case reports in pediatrics· 2026· PMID 41523963mais citado
  6. Hermansky-Pudlak Syndrome Type 3 Complicated by Schizophrenia and Crohn's-Like Colitis.
    J Dermatol· 2026· PMID 41906413recente
  7. Haplotype-Based Analysis of OCA2 Variants in Oculocutaneous Albinism.
    Pigment Cell Melanoma Res· 2026· PMID 41905947recente
  8. Quantifying functional vision in a mouse model of oculocutaneous albinism type 1.
    Sci Rep· 2026· PMID 41872298recente
  9. The impact of stigma on people with albinism in Africa: a narrative review.
    J Community Genet· 2026· PMID 41863705recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:55(Orphanet)
  2. MONDO:0018910(MONDO)
  3. GARD:10958(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q2017741(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Albinismo oculocutâneo
Compêndio · Raras BR

Albinismo oculocutâneo

ORPHA:55 · MONDO:0018910
Prevalência
1-9 / 100 000
Herança
Autosomal recessive
CID-10
E70.32 · Distúrbios do metabolismo de aminoácidos aromáticos
CID-11
Ensaios
2 ativos
Medicamentos
3 registrados
Início
Neonatal
Prevalência
5.9 (Worldwide)
MedGen
UMLS
C0078918
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades